-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 24, Kelun Pharmaceutical issued an announcement that its subsidiary Hunan Kelun Pharmaceutical recently obtained the "Drug Registration Certificate" for the chemical drug "Sunitinib Malate Capsules" approved and issued by the National Medical Products Administration.
It is understood that sunitinib malate capsules developed by Pfizer, approved in the United States in 2006, after another in Japan, Europe approved the listing Union and other countries and regions, in 2007 the country approved import for inoperable fine advanced renal cell carcinoma, imatinib mesylate stromal tumors and metastatic unresectable between high failure or intolerant gastrointestinal differentiation of pancreatic neuroendocrine tumor progression.
Union and other countries and regions approved on the market, in 2007 the country imported approved for advanced renal fine inoperable cancer cells, imatinib mesylate treatment failure or intolerance between gastrointestinal stromal tumors and unresectable high metastatic differentiated advanced pancreatic neuroendocrine tumors.
